[{"id":"07a51dc9-114c-48cd-acba-f59680179bb5","acronym":"INNATE","url":"https://clinicaltrials.gov/study/NCT04669899","created_at":"2021-07-23T15:52:37.047Z","updated_at":"2024-07-02T16:35:10.864Z","phase":"Phase 1/2","brief_title":"Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors","source_id_and_acronym":"NCT04669899 - INNATE","lead_sponsor":"Jounce Therapeutics, Inc.","biomarkers":" EGFR • PD-L1 • ALK • IDH1 • FGFR","pipe":" | ","alterations":" EGFR mutation • IDH1 mutation • ALK rearrangement • FGFR mutation","tags":["EGFR • PD-L1 • ALK • IDH1 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • IDH1 mutation • ALK rearrangement • FGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pimivalimab (JTX-4014) • polzastobart (JTX-8064)"],"overall_status":"Completed","enrollment":" Enrollment 190","initiation":"Initiation: 01/12/2021","start_date":" 01/12/2021","primary_txt":" Primary completion: 11/28/2023","primary_completion_date":" 11/28/2023","study_txt":" Completion: 11/28/2023","study_completion_date":" 11/28/2023","last_update_posted":"2024-04-09"}]